| Detailed information |
|---|
| CancerLivER ID | 2499 |
| Biomarker | SEMA3F, DDX17, TNFAIP, PDGFRA, VIM, LAPTM5, CCND2, HLADRA, MEF2C, Staf50, SGK, REL, |
| Biomarker Name/Symbol (given in Publication) | 12 gene signature (SEMA3F, DDX17, TNFAIP, PDGFRA, VIM, LAPTM5, CCND2, HLADRA, MEF2C, Staf50, SGK, REL) |
| Biomolecule | RNAs |
| Subject | Human |
| Degree of Validity | Gene signature can serve for characterising the metastatic potential of hepatocellular carcinoma and predict recurrence and validated on independent dataset |
| Experimental Condition | Early intrahepatic recurrence and non-recurrence HCC |
| Cancer type | Hepatocellular carcinoma |
| Regulation | Diffrenetially Expressed between recurrent and non-recurrent HCC |
| Level of significance | p < 0.05 |
| Source | Tissue |
| PMID | 12648972 |
| Type of Biomarker | Prognostic |
| Pathway | NA |
| Cohort | Training dataset: 33 HCC patients ( 12 Early intrahepatic recurrence and 21 non-recurrence HCC); Validation dataset: 27 HCC patients ( 8 Early intrahepatic recurrence and 19 non-recurrence HCC) |
| Sensitivity | 88% |
| Specificity | 95% |
| Accuracy | 93% |
| AUC | NA |
| Disease | Early recurrence of HCC v/s no recurrence of HCC |
| Year of Publication | 2003 |
| Clinical trial | NO |
| Clinical trial (NCT Number) | NA |